Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Regulus Therapeutics (NQ: RGLS )

1.300 USD +0.090 (+7.44%)
Official Closing Price Updated: 4:53 PM EDT, Apr 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 719,220
Open 1.210
Bid (Size) 1.230 (1)
Ask (Size) 1.340 (2)
Prev. Close 1.210
Today's Range 1.190 - 1.310
52wk Range 0.4200 - 2.320
Shares Outstanding 72,504,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced... 
From PR Newswire
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan,... 
From PR Newswire

Performance

YTD
N/A
N/A
1 Month
-27.37%
-27.37%
3 Month
+10.17%
+10.17%
6 Month
+145.28%
+145.28%
1 Year
+182.61%
+182.61%

More News

Read More
3 Penny Stocks to Buy for Under $2 But Are They Worth It?
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
From PR Newswire
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
From PR Newswire
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
From PR Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Tags DBVT GEG Movers
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Tags SMTI Market News ENTX
From Benzinga
RGLS Stock: 7 Things to Know About Red-Hot Regulus Therapeutics
Tags SNY Today's Market RGLS
From InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Tags SDGR SLRX RGLS
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Tags MTP EVGN TWST
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.